LAG3 and metastatic melanoma: Despite suboptimal outcomes with monotherapy, the combination of relatlimab (LAG‐3 inhibitor) and nivolumab (Opdualag) was approved for the management of unresectable or metastatic melanoma in 2022, marking a significant milestone [45].